- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$54.90 MnMarket Estimate, 2026
$60.53 MnMarket Forecast, 2034
$132.13 MnCAGR, 2026–2034
10.25%Executive Summary: Latin America Mycoplasma Testing Market
- Market Scope: Regional analysis of Latin America's mycoplasma testing sector, detailing product categories, testing techniques, applications, end-user segments, and country-level profiles.
- Market Valuation: Valued at USD 54.90 million in 2025, reaching USD 60.53 million in 2026, and projected to expand to USD 132.13 million by 2034, growing at a robust CAGR of 10.25% from 2026 to 2034.
- Primary Growth Drivers: Increased R&D activity by pharmaceutical and biotechnology companies, rising government support and funding, growing cell culture contamination concerns, and post-COVID-19 co-infection diagnostics.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment |
|---|---|---|
| By Product | Kits & Reagents (dominated in 2026, driven by high consumption of PCR assays and nucleic acid detection kits) | Services (anticipated at a high CAGR, fueled by specialized outsourced contamination testing and regulatory support) |
| By Technique | PCR (held the dominant share in 2026, anchored by high sensitivity, specificity, and rapid turnaround times) | Direct & Indirect Assays (expected to register strong growth due to comprehensive diagnostic reliability) |
| By Application | Cell Line Testing (captured the major market share in 2026, supported by extensive biopharmaceutical research) | Virus Testing (projected at an extraordinary CAGR, propelled by vaccine development and viral safety screening) |
| By End-User | Pharmaceutical Companies (market leader with the highest share in 2026, backed by extensive drug manufacturing pipelines) | Contract Research Organizations (key growth segment driven by increased outsourcing of safety and quality control testing) |
| By Country | Brazil (market leader with the highest share in 2026, backed by a well-established healthcare industry and research investments) | Mexico & Argentina (key regional hubs driven by technological advancements in cell culture and government-funded biomedical aids) |
Major Market Players & Industry Landscape
Market Structure: Highly consolidated environment characterized by established global players with strong brand loyalty, creating barriers to entry while encouraging continuous product innovation.
Key Companies: PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, and WuXi AppTec.
Latin America Mycoplasma Testing Market Size
The Latin America Mycoplasma Testing Market is projected to grow from USD 54.90 million in 2025 to USD 60.53 million in 2026 and reach USD 132.13 million by 2034, registering a CAGR of 10.25% during the forecast period from 2026 to 2034.
MARKET DRIVERS:
Increased research activity by pharmaceutical and biotechnology companies, increased government support and funding for research activities, and growing contamination of cell cultures worldwide are the few factors primarily driving the Latin American mycoplasma testing market. The growth of the Latin American mycoplasma testing market is driven by growing concerns over contamination of cell cultures, the growth of pharmaceutical and biotechnology industries, and increasing pharmaceutical R&D activities and investments.
Unlike other sectors, the ongoing pandemic due to the novel coronavirus, the Latin American mycoplasma testing market has seen unexpected growth resulting from post covid complications in patients across the world, especially in developing countries.
Recently, several reports have reminded clinicians of the possibility of co-infection with other pathogens (such as Mycoplasma pneumonia) in COVID-19 patients. This means the need to screen patients with symptoms of COVID-19 (if they have pneumonia) for mycoplasmas. These cases are expected to stimulate demand for mycoplasma testing as part of the diagnosis/pathology. The increasing rate of co-infections in COVID-19 cases, with a significant likelihood of being caused by Mycoplasma pneumoniae, is expected to drive demand for mycoplasma testing in several countries around the world over the coming months. The growing need for testing will create lucrative opportunities for the market, eventually leading to the market's exponential growth.
MARKET RESTRAINTS:
However, a high degree of consolidation acts and a strict regulatory framework are the few factors expected to hamper the Latin American mycoplasma testing market growth during the forecast period 2026-2034. The regulation is restrictive in nature and therefore avoids using other testing methods that could potentially accurately detect mycoplasmas. These changes in the regulation of biologics are expected to improve the sensitivity and specificity of mycoplasma testing by developing new technologies. Therefore, an increase in public funding for pharmaceutical and biotechnology research has stimulated R&D activities, promoting the wide application of mycoplasma test products.
The major challenge to the Latin American mycoplasma testing market is large and well-established companies and enjoy a high degree of brand loyalty. New entrants in this market compete with existing testing products and distinguish themselves by developing innovative product offers. The high degree of consolidation is a major barrier to entry for new testing kits, which should restrict investments and therefore slow the growth potential of this market.
MARKET SEGMENTATION
This research report on the Latin America Mycoplasma Testing Market has been segmented and sub-segmented into the following categories:
By Product:
- Kits & Reagent
- PCR Assays
- Nucleic Acid Detection Kits
- Elimination Kits & Reagents
- Stains
- Standards & Controls
- Other Kits & Reagents
- Instruments
- Services
By Technique:
- PCR
- ELSA
- Direct Assays
- Indirect Assays
- Microbial culture techniques
- Enzymatic Methods
- DNA Staining
By Application:
- Cell Line Testing
- Virus Testing
- End-Of-Production Cell Testing
- Others
By End-User:
- Pharmaceutical Companies
- Contract Research Organizations
- Academic Research Institutes
- Cell Banks
By Country:
- Mexico
- Brazil
- Argentina
- Chile
- Rest of Latin America
Regional Analysis:
In Latin America, the Brazilian mycoplasma testing market is expected to grow to occupy the leading share during the forecast period due to its well-established healthcare industry and the increasing prevalence of chronic diseases in the region. In addition, biotechnology companies and pharmaceutical players and increased investments are expected to boost regional market growth. Due to increased technological advancements in cell culture and government-funded aids in drug research development, growth is seen in populated regions such as Columbia, Mexico, and Argentina.
KEY MARKET PLAYERS:
A few of the noteworthy companies dominating the Latin America Mycoplasma Testing Market profiled in this report are PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, and WuXi AppTec.